Related Experiment Video
Updated: May 5, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Regulatory forum commentary: is unexpected immunostimulation manageable in pharmaceutical development?
1Immunotoxicology Center of Emphasis, Pfizer Worldwide Research & Development, Drug Safety Research & Development, Groton, Connecticut, USA Ellen.w.evans@pfizer.com.
Interpreting unexpected immunostimulation during drug development is challenging. Understanding drug mechanisms and careful monitoring can help successfully develop drugs exhibiting immunostimulatory effects.
Area of Science:
- Immunology
- Pharmacology
- Toxicology
Background:
- Drug development faces challenges in interpreting unexpected immunostimulation.
- Immunostimulatory findings can arise from unknown drug mechanisms of action.
Purpose of the Study:
- To describe various types of immunostimulation.
- To present a risk assessment strategy for managing unexpected immunostimulation in toxicity studies.
Main Methods:
- Review of existing literature on drug-induced immunostimulation.
- Development of a risk assessment framework for unexpected findings.
Main Results:
- Unexpected immunostimulation does not automatically halt drug development.
- Successful drug development is possible with a thorough understanding of mechanisms, patient populations, and species differences.
Conclusions:
- A strategic approach to risk assessment and clinical monitoring is crucial for managing immunostimulatory effects.
- Understanding the nuances of immunostimulation aids in the successful progression of drug candidates.
Related Concept Videos
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Products: Biologics, Biosimilars and Interchangeables
Dosage Regimen: Individualization
Preclinical Development: Overview

